Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

NCT06271616 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Chronic Graft Versus Host Disease
Hematopoietic and Lymphatic System Neoplasm

Interventions

PROCEDURE: Echocardiography Test
DRUG: Ibrutinib

Sponsor

Mayo Clinic